Powder: -20°C for 3 years | In solvent: -80°C for 1 year
K134 is an inhibitor of phosphodiesterase 3. The IC50s of K134 for PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, <300 and <300 μM, respectively.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 3,190 | 5日内发货 | ||
25 mg | ¥ 11,700 | 6-8周 | ||
50 mg | ¥ 15,300 | 6-8周 | ||
100 mg | ¥ 19,500 | 6-8周 |
产品描述 | K134 is an inhibitor of phosphodiesterase 3. The IC50s of K134 for PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively. |
靶点活性 | PDE3A:0.1 μM, PDE3B:0.28 μM, PDE5:12.1 μM |
体外活性 | K134 (K-134) inhibits rat platelet aggregation caused by collagen and ADP in a dose-dependent manner in vitro. K134 also inhibits mouse platelet aggregation induced by collagen and ADP in a dose-dependent manner (IC50s: 5.5 μM and 6.7 μM, respectively), in vitro experiments. The half-maximal (50%) inhibitory concentration (IC50) values of K134 are 2.5 μM and 3.2 μM, respectively [1]. |
体内活性 | K134 obviously decreases the incidence of occlusive shunt thrombi at doses above 10 mg/kg (half-maximal effective dose: ED50=11 mg/kg). The effects of PDE3 inhibitors on thrombus formation are also investigated in an arteriovenous shunt model in rats. The plasma concentration of K134 is 0.43±0.08 μM (Cmax) at a dose of 10 mg/kg. K134 obviously prolongs middle cerebral artery (MCA) occlusion time at doses >10 mg/kg and decreases cerebral infarct size at 30 mg/kg in the stroke model (n?=?12, 87.5±5.6 vs. 126.8±7.5 mm3, P<0.01), indicating its potent antithrombotic effect. The overall bleeding risk of K134 is assessed in general in mice. K134 (30 mg/kg; Single oral administration) does not prolong bleeding time at a dose of compared to control (106±5 vs. 110±5 s, not significant). A sufficiently high enough plasma concentration of K134 (13.6±2.3 μM) is detected to inhibit platelet aggregation at 10 min after single administration in mice at a dose of 30 mg/kg, which is the same time point as the above test of bleeding time [1]. |
别名 | OPC33509 |
分子量 | 399.48 |
分子式 | C22H29N3O4 |
CAS No. | 189362-06-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
K134 189362-06-9 Metabolism PDE K 134 OPC33509 OPC-33509 K-134 OPC 33509 Inhibitor inhibitor inhibit